Actavis Price Target Increased to $170.00 by Analysts at Susquehanna (ACT)
Stock analysts at Susquehanna hoisted their target price on shares of Actavis (NYSE:ACT) from $165.00 to $170.00 in a report issued on Wednesday, AR Network reports. The firm currently has a “neutral” rating on the stock. Susquehanna’s price objective would indicate a potential upside of 8.54% from the stock’s previous close.
A number of other analysts have also recently weighed in on ACT. Analysts at JPMorgan Chase & Co. raised their price target on shares of Actavis from $160.00 to $170.00 in a research note to investors on Wednesday. They now have an “overweight” rating on the stock. Separately, analysts at Zacks reiterated an “outperform” rating on shares of Actavis in a research note to investors on Wednesday. They now have a $185.00 price target on the stock. Finally, analysts at Jefferies Group reiterated an “in-line” rating on shares of Actavis in a research note to investors on Wednesday. They now have a $168.00 price target on the stock, up previously from $133.00. Six equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $154.67.
Actavis (NYSE:ACT) traded up 1.53% during mid-day trading on Wednesday, hitting $156.63. The stock had a trading volume of 2,162,136 shares. Actavis has a 1-year low of $80.81 and a 1-year high of $139.10. The stock’s 50-day moving average is $135.2 and its 200-day moving average is $116.2. The company’s market cap is $20.856 billion.
Actavis (NYSE:ACT) last announced its earnings results on Tuesday, October 29th. The company reported $2.09 earnings per share for the quarter, meeting the analysts’ consensus estimate of $2.09. The company had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $2.04 billion. Actavis’s revenue was up 56.7% compared to the same quarter last year. On average, analysts predict that Actavis will post $8.35 earnings per share for the current fiscal year.
Actavis, Inc formerly Watson Pharmaceuticals, Inc, is a integrated global specialty pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic, branded generic, brand, biosimilar and over-the-counter (NYSE:ACT) pharmaceutical products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.